用于乳腺癌诊断和预后的循环tRNA衍生小RNA（tsRNAs）特征
Circulating tRNA-derived small RNAs (tsRNAs) signature for the diagnosis and prognosis of breast cancer.
作者信息
Wang Jingyi, Ma Ge, Ge Han, Han Xu, Mao Xinrui, Wang Xinyang, Veeramootoo Jordee Selvamanee, Xia Tiansong, Liu Xiaoan, Wang Shui
机构信息
Department of Breast Surgery, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, 210029, Nanjing, China.
Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Jiangsu Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, 211166, Nanjing, China.
出版信息
NPJ Breast Cancer. 2021 Jan 5;7(1):4. doi: 10.1038/s41523-020-00211-7.
Liquid biopsy is noninvasive and convenient to detect cancer-derived materials in blood or other body fluids. The aim of this study was to identify tRNA-derived small RNAs (tsRNAs) in plasma that could distinguish patients with breast cancer (BC) from healthy controls. Basing on high-throughput sequencing, 15 significantly upregulated tsRNAs were selected and assessed in cell supernatants and cell lines. 6 tsRNAs were identified and verified in a large cohort of 120 patients with BC and 112 healthy controls. tRF-Arg-CCT-017, tRF-Gly-CCC-001, and tiRNA-Phe-GAA-003 could serve as novel diagnostic biomarkers. Meanwhile, tRF-Arg-CCT-017 and tiRNA-Phe-GAA-003 could also act as prognostic biomarkers. Target genes of these tsRNAs were related to the development of cancers. These results suggested that specific tsRNAs in plasma might serve as diagnostic and prognostic biomarkers of BC.
液体活检是非侵入性的，便于检测血液或其他体液中源自癌症的物质。本研究的目的是鉴定血浆中可将乳腺癌（BC）患者与健康对照区分开来的tRNA衍生小RNA（tsRNAs）。基于高通量测序，在细胞上清液和细胞系中选择并评估了15种显著上调的tsRNAs。在120例BC患者和112例健康对照的大型队列中鉴定并验证了6种tsRNAs。tRF-Arg-CCT-017、tRF-Gly-CCC-001和tiRNA-Phe-GAA-003可作为新型诊断生物标志物。同时，tRF-Arg-CCT-017和tiRNA-Phe-GAA-003也可作为预后生物标志物。这些tsRNAs的靶基因与癌症的发展有关。这些结果表明，血浆中的特定tsRNAs可能作为BC的诊断和预后生物标志物。
Zotero 插件